Table 1 Details of studies on the relationship between MDT discussion and outcome in patients with colorectal cancer
Author | Country | Setting | Period | Patients | Comparison | Factors significant in MVA | Survival outcome | HR death any cause (95 % c.i.) |
|---|---|---|---|---|---|---|---|---|
Ye | China | Hospital-based | 1999–2006 | after radical resection for colorectal cancer | before MDT introduced in 2002 (n = 297) cf. after MDT (n = 298) | MDT, Age, Differentiation, Number of nodes examined, Stage | OS | 0.62 (0.46 to 1.48) |
Du | China | Hospital-based | 2001–2005 | with resectable locally advanced rectal cancer | contemporaneous patients; n = 101 were evaluated by MDT members and were treated with neoadjuvant chemotherapy; n = 162 were not evaluated | EMVI, pre-treatment CEA, pathological TNM stage | OS, DFS | 0.88 (0.52 to 1.48) |
Lordan | England | Hospital-based | 1996–2006 | with hepatic metastases from colorectal cancer who were referred for liver surgery | those who were referred by a team which contained a HPB surgeon (n = 108); those who were referred by teams lacking a HPB surgeon (n = 223) | recurrence, septicaemia, pre-operative chemotherapy, referral via team with HPB surgeon, macroscopic invasion of diaphragm | OS, DFS | 0.85 (0.60 to 1.19) |
McDermid | Scotland | Surgeon-based | 1997–2005 | with resected colorectal cancers (excluding Dukes’A) | before MDT introduced in 2002 (n = 176) cf. after MDT (n = 134) | Age, stage, MDT | OS | 0.73 (0.54 to 0.99) |
Palmer | Sweden | Regional | 1995–2004 | with rectal cancer invading into adjacent organs | 3 groups 1) n = 65 discussed at MDT appropriately staged 2) n = 99 appropriately staged not discussed at MDT 3) n = 139 not appropriately staged (whether or not discussed at MDT) | Age | OS (CSS for MVA) | 0.95 (0.62 to 1.45) |
Wille-Jorgensen | Denmark | Hospital | 2001–2006 | Rectal cancer | Before MDT introduced (n = 467) c.f.after MDT introduced (n = 344) | No MVA | OS | 0.94 (0.79 to 1.12) |